BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36185186)

  • 1. Clinical features and surgical outcomes of young patients with lung adenocarcinoma manifesting as ground glass opacity.
    Qu R; Tu D; Cai Y; Ping W; Fu X
    Front Oncol; 2022; 12():979522. PubMed ID: 36185186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and prognosis of ground-glass opacity nodules in young patients.
    Wang J; Ma H; Ni CJ; He JK; Ma HT; Ge JF
    J Thorac Dis; 2019 Feb; 11(2):557-563. PubMed ID: 30963000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct cellular immune profiles in lung adenocarcinoma manifesting as pure ground glass opacity versus solid nodules.
    Qu R; Ye F; Hu S; Wang B; Qin S; Xiong J; Fu X; Li L; Cai Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3775-3788. PubMed ID: 35986758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ground glass opacity resection extent assessment trial
    Li H; Wang Y; Chen Y; Zhong C; Fang W
    Front Oncol; 2023; 13():1052796. PubMed ID: 36741022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a ground-glass opacity component on the recurrence and survival of pathological stage IA3 lung adenocarcinoma: a multi-institutional retrospective study.
    Xu SJ; Chen RQ; Tu JH; You CX; Chen C; Zhang ZF; Divisi D; Migliore M; Bongiolatti S; Durand M; Sato M; Kuroda H; Yang CF; Yu SB; Chen SC
    Transl Lung Cancer Res; 2023 May; 12(5):1078-1092. PubMed ID: 37323166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence Patterns and Patient Outcomes in Resected Lung Adenocarcinoma Differ according to Ground-Glass Opacity at CT.
    Park S; Lee SM; Choe J; Choi S; Do KH; Seo JB
    Radiology; 2023 May; 307(3):e222422. PubMed ID: 36943079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Nomograms Based on Ground Glass Opacity and Subtype of Lung Adenocarcinoma for Patients with Pathological Stage IA Lung Adenocarcinoma.
    Zhai W; Liang D; Duan F; Wong W; Yan Q; Gong L; Lai R; Dai S; Long H; Wang J
    Front Cell Dev Biol; 2021; 9():769881. PubMed ID: 34957101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary lung cancer in children and adolescents.
    Chen Q; Cheng J; Wang L; Lv X; Hu J
    J Cancer Res Clin Oncol; 2024 May; 150(5):225. PubMed ID: 38695944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ground glass opacity featured lung adenocarcinoma in teenagers.
    Wu H; Zhang Y; Hu H; Li Y; Shen X; Liu Q; Wang S; Chen H
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3719-3724. PubMed ID: 33829316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological characteristics and prognosis of non-lepidic invasive adenocarcinoma presenting as ground glass opacity nodule.
    Moon Y; Sung SW; Lee KY; Park JK
    J Thorac Dis; 2016 Sep; 8(9):2562-2570. PubMed ID: 27747010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological and radiological T descriptors in invasive lung adenocarcinoma: from correlations to prognostic significance.
    Ma Z; Han H; Cao H; Wang S; Li Y; Zhang Y; Chen H
    Transl Lung Cancer Res; 2023 Nov; 12(11):2181-2192. PubMed ID: 38090517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should resection extent be decided by total lesion size or solid component size in ground glass opacity-containing lung adenocarcinomas?
    Lin B; Wang R; Chen L; Gu Z; Ji C; Fang W
    Transl Lung Cancer Res; 2021 Jun; 10(6):2487-2499. PubMed ID: 34295656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic effect of ground-glass opacity in subcentimeter invasive lung adenocarcinoma.
    Bai J; Fu F; Sun W; Deng C; Ma Z; Wang S; Deng L; Zhang Y; Chen H
    J Thorac Dis; 2023 Apr; 15(4):1559-1571. PubMed ID: 37197537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non-Small Cell Lung Cancer.
    Aokage K; Miyoshi T; Ishii G; Kusumoto M; Nomura S; Katsumata S; Sekihara K; Tane K; Tsuboi M
    J Thorac Oncol; 2018 Apr; 13(4):533-542. PubMed ID: 29246833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological features and prognostic implications of ground-glass opacity components on computed tomography for clinical stage I lung adenocarcinoma.
    Katsumata S; Aokage K; Ishii G; Hoshino H; Suzuki J; Miyoshi T; Tane K; Samejima J; Tsuboi M
    Surg Today; 2021 Jul; 51(7):1188-1202. PubMed ID: 33745094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of wedge resection for pulmonary ground-glass opacity nodules.
    Cho JH; Choi YS; Kim J; Kim HK; Zo JI; Shim YM
    Ann Thorac Surg; 2015 Jan; 99(1):218-22. PubMed ID: 25440277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct clinicopathologic factors and prognosis based on the presence of ground-glass opacity components in patients with resected stage I non-small cell lung cancer.
    Wang C; Wu Y; Li J; Ren P; Gou Y; Shao J; Zhou Y; Xiao X; Tuersun P; Liu D; Zhang L; Li W
    Ann Transl Med; 2020 Sep; 8(18):1133. PubMed ID: 33240982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 lung adenocarcinoma?
    Nakamura S; Fukui T; Kawaguchi K; Fukumoto K; Hirakawa A; Yokoi K
    Lung Cancer; 2015 Jul; 89(1):38-42. PubMed ID: 25963638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Ground-Glass Opacities in the Lung Cancer Spectrum.
    Zhang Y; Fu F; Chen H
    Ann Thorac Surg; 2020 Dec; 110(6):1796-1804. PubMed ID: 32525031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma.
    Hattori A; Hirayama S; Matsunaga T; Hayashi T; Takamochi K; Oh S; Suzuki K
    J Thorac Oncol; 2019 Feb; 14(2):265-275. PubMed ID: 30368010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.